Development Research Program

发展研究计划

• 批准号: 10452723
• 负责人: WILLIAM A CLIBY
• 金额: $ 14.75万
• 依托单位: MAYO CLINIC ROCHESTER
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-07-01 至 2026-08-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10452723
• 关键词: Advisory Committees; Award; Cancer Patient; Chicago; Clinic; Clinical Investigator; Clinical Research; Clinical Trials; Collaborations; Communities; Creativeness; Data; Development; Direct Costs; Disabled Persons; Disease; Extramural Activities; Facilities and Administrative Costs; Fostering; Funding; Goals; Grant; Human Resources; Individual; Institution; Intervention; Laboratory Study; Letters; Malignant neoplasm of ovary; Mayo Clinic Cancer Center; Measures; Minnesota; Minority; Monitor; Ovarian; Patient advocacy; Patients; Peer Review; Pilot Projects; Policies; Population; Population Study; Process; Program Research Project Grants; Publications; Recommendation; Research; Research Personnel; Research Project Grants; Research Support; Stimulus; System; Testing; TimeLine; Translating; Translational Research; United States National Institutes of Health; Universities; Woman; Work; anticancer research; base; clinically relevant; experience; improved; innovation; interdisciplinary collaboration; interest; originality; programs; research and development; sound; success; translational goal; translational pipeline; translational potential

ABTRACT – DEVELOPMENTAL RESEARCH PROGRAM (DRP) The purpose of the Developmental Research Program (DRP) in the Mayo Clinic SPORE in Ovarian Cancer is to support innovative, scientifically sound research projects from which findings can be translated into clinically relevant interventions that will reduce the burden of ovarian cancer. This program has been highly successful, with support going to 38 DRP projects in Years 6-10. Among the DRP project teams, 21 (11 funded in Years 1- 5 and 10 funded in Years 6-10) have received additional funding outside of the SPORE in Years 6-10 based on their DRP project and 5 provided data instrumental for the selection of the full research projects in this renewal. In our second funding period, the DRP generated 74 associated publications and contributed to 7 SPORE- associated clinical trials. We will build on the successes of our SPORE DRP, which has attracted investigators new to ovarian cancer research who ultimately became co-Leaders or co-Investigators of full Projects included in this SPORE application, Core co-Leaders, or were awarded NIH funding outside of the SPORE. The DRP will 1) foster innovative laboratory, population, and clinical study proposals that have strong translational potential; 2) encourage and support interdisciplinary collaboration in translational research in ovarian cancer; and 3) generate new hypotheses that can be tested in larger scale research projects or clinical trials in ovarian cancer. The DRP will provide $200,000 annually ($100,000 from the SPORE and a matching $100,000 from Mayo Clinic) to support at least 4 meritorious projects with $50,000 each to be used within one year. In addition, between August 2014 and July 2020 we raised philanthropic support for ovarian cancer research at Mayo Clinic that supported 18 DRP awards above and beyond the 20 originally projected during Years 6-10; and we will continue to seek additional support for ovarian cancer research in the years to come. Depending on the progress of any given project, the possibility of a second year of support exists via competitive review of both new and continuation projects. The DRP will continue to utilize a defined process to call for applications on an annual basis and to review submissions, utilizing the expertise of the Internal Scientific Advisory Committee, Executive Committee, Patient Advocacy Advisory Committee, and other experienced investigators as needed. Criteria for DRP awards include: The likelihood that the work will impact major challenges in ovarian cancer, scientific merit, originality, translational potential, qualifications of the key personnel, and interactivity. As experienced in our second funding period, it is anticipated that support of DRP projects through this program will generate new hypotheses that progress to full SPORE translational projects or to peer- reviewed external grant support.

摘要 – 发展研究计划 (DRP) Mayo Clinic SPORE 卵巢癌发展研究计划 (DRP) 的目的是 支持创新、科学合理的研究项目，将研究结果转化为临床 相关干预措施将减轻卵巢癌的负担。 在第 6-10 年为 38 个 DRP 项目提供支持 在 DRP 项目团队中，有 21 个项目（第 1-10 年资助了 11 个）。 5 和 10 在第 6-10 年获得资助) 在第 6-10 年获得了 SPORE 之外的额外资助 他们的 DRP 项目和 5 提供了有助于选择本次更新中完整研究项目的数据。 在我们的第二个资助期，DRP 出版了 74 份相关出版物，并为 7 SPORE- 我们将在 SPORE DRP 的成功基础上开展相关临床试验，该试验已吸引了研究人员。 最终成为卵巢癌研究的新手，并最终成为整个项目的联合领导者或联合研究者 在此 SPORE 申请中，核心联合领导者或在 DRP 之外获得 NIH 资助。 将 1) 培育具有强大转化能力的创新实验室、人群和临床研究提案 潜力；2）鼓励和支持卵巢癌转化研究的跨学科合作； 3）产生可以在更大规模的卵巢研究项目或临床试验中进行测试的新假设 DRP 每年将提供 200,000 美元（其中 100,000 美元来自 SPORE，配套的 100,000 美元来自 SPORE）。 Mayo Clinic）支持至少 4 个优秀项目，每个项目在一年内使用 50,000 美元。 此外，2014 年 8 月至 2020 年 7 月期间，我们为卵巢癌研究筹集了慈善支持 梅奥诊所支持了 18 个 DRP 奖项，超出了第 6-10 年最初预计的 20 个奖项； 我们将在未来几年继续为卵巢癌研究寻求更多支持。 对于任何特定项目的进展，都可以通过竞争性审查获得第二年的支持 新项目和延续项目将继续利用既定流程来征集申请。 每年一次，并利用内部科学咨询的专业知识审查提交的材料 委员会、执行委员会、患者权益咨询委员会和其他经验丰富的调查人员 根据需要，DRP 奖项的标准包括： 该工作影响重大挑战的可能性。 卵巢癌、科学价值、原创性、转化潜力、关键人员的资格，以及 正如我们在第二个资助期所经历的那样，预计将通过 DRP 项目提供支持。 该计划将产生新的假设，这些假设将进展为完整的 SPORE 转化项目或同行- 审查了外部赠款支持。